Carib A. Oquendo

Array ( [id] => 9003064 [patent_doc_number] => 20130224189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-29 [patent_title] => 'TWEAK RECEPTOR' [patent_app_type] => utility [patent_app_number] => 13/783105 [patent_app_country] => US [patent_app_date] => 2013-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 21065 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13783105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8916320 [patent_doc_number] => 20130177944 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-11 [patent_title] => 'ANTI-CD4 ANTIBODY' [patent_app_type] => utility [patent_app_number] => 13/755472 [patent_app_country] => US [patent_app_date] => 2013-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 37045 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13755472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8791658 [patent_doc_number] => 20130108627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-02 [patent_title] => 'HUMANIZED PCRV ANTIBODY HAVING ANTI-PSEUDOMONAL ACTIVITY' [patent_app_type] => utility [patent_app_number] => 13/734872 [patent_app_country] => US [patent_app_date] => 2013-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 12010 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13734872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8820964 [patent_doc_number] => 20130122009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-16 [patent_title] => 'Engineered Anti-IL-23p19 Antibodies' [patent_app_type] => utility [patent_app_number] => 13/717131 [patent_app_country] => US [patent_app_date] => 2012-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 20185 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13717131 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9922302 [patent_doc_number] => 08980258 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-03-17 [patent_title] => 'Bispecific single chain Fv antibody molecules and methods of use therof' [patent_app_type] => utility [patent_app_number] => 13/710146 [patent_app_country] => US [patent_app_date] => 2012-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 17 [patent_no_of_words] => 22910 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13710146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8950070 [patent_doc_number] => 20130195850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-01 [patent_title] => 'CD3 IMMUNOTHERAPEUTICS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/678128 [patent_app_country] => US [patent_app_date] => 2012-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 28265 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13678128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9093748 [patent_doc_number] => 20130273060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-17 [patent_title] => 'NOVEL ANTIBODIES INHIBITING C-MET DIMERIZATION, AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/673726 [patent_app_country] => US [patent_app_date] => 2012-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 72 [patent_figures_cnt] => 72 [patent_no_of_words] => 33257 [patent_no_of_claims] => 56 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13673726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10069572 [patent_doc_number] => 09107907 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-08-18 [patent_title] => 'Antibodies inhibiting c-Met dimerization, and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/673752 [patent_app_country] => US [patent_app_date] => 2012-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 72 [patent_figures_cnt] => 112 [patent_no_of_words] => 33240 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13673752 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10844732 [patent_doc_number] => 08871910 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-10-28 [patent_title] => 'Antibodies inhibiting c-Met dimerization, and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/673716 [patent_app_country] => US [patent_app_date] => 2012-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 72 [patent_figures_cnt] => 112 [patent_no_of_words] => 33224 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13673716 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10844730 [patent_doc_number] => 08871909 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-10-28 [patent_title] => 'Antibodies inhibiting c-Met dimerization and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/673690 [patent_app_country] => US [patent_app_date] => 2012-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 72 [patent_figures_cnt] => 108 [patent_no_of_words] => 33229 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13673690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8707533 [patent_doc_number] => 20130064822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-14 [patent_title] => 'HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME' [patent_app_type] => utility [patent_app_number] => 13/668129 [patent_app_country] => US [patent_app_date] => 2012-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 50595 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13668129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8828704 [patent_doc_number] => 20130129749 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-23 [patent_title] => 'HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME' [patent_app_type] => utility [patent_app_number] => 13/668086 [patent_app_country] => US [patent_app_date] => 2012-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 50588 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13668086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8828688 [patent_doc_number] => 20130129733 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-23 [patent_title] => 'HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME' [patent_app_type] => utility [patent_app_number] => 13/668064 [patent_app_country] => US [patent_app_date] => 2012-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 50608 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13668064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9318782 [patent_doc_number] => 20140051120 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-20 [patent_title] => 'HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME' [patent_app_type] => utility [patent_app_number] => 13/668054 [patent_app_country] => US [patent_app_date] => 2012-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 50908 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13668054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8865604 [patent_doc_number] => 20130149307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-13 [patent_title] => 'HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME' [patent_app_type] => utility [patent_app_number] => 13/668028 [patent_app_country] => US [patent_app_date] => 2012-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 50941 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13668028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8792875 [patent_doc_number] => 20130109844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-02 [patent_title] => 'ANTI-cMET ANTIBODY' [patent_app_type] => utility [patent_app_number] => 13/619920 [patent_app_country] => US [patent_app_date] => 2012-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 25199 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13619920 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8792872 [patent_doc_number] => 20130109841 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-02 [patent_title] => 'ANTI-cMET ANTIBODY' [patent_app_type] => utility [patent_app_number] => 13/619910 [patent_app_country] => US [patent_app_date] => 2012-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 25192 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13619910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9523592 [patent_doc_number] => 08747850 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-06-10 [patent_title] => 'Anti-cMET antibody' [patent_app_type] => utility [patent_app_number] => 13/619730 [patent_app_country] => US [patent_app_date] => 2012-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 46 [patent_no_of_words] => 25283 [patent_no_of_claims] => 56 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13619730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8903644 [patent_doc_number] => 20130171146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-04 [patent_title] => 'DUAL-SPECIFIC IL-1A/ IL-1B ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/591027 [patent_app_country] => US [patent_app_date] => 2012-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 67669 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13591027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8509071 [patent_doc_number] => 20120308480 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-06 [patent_title] => 'HUMANIZED ANTIBODIES AGAINST TL1A' [patent_app_type] => utility [patent_app_number] => 13/585792 [patent_app_country] => US [patent_app_date] => 2012-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 7996 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13585792 [rel_patent_id] =>[rel_patent_doc_number] =>)